Anthem Bioscienc (ANTHEM)

FairStock Score: 19/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Fellow investor, when I look at Anthem Bioscienc, I begin with Graham's question: what am I getting for ₹890.10 per share? Market cap is ₹49,998 Cr, book value only ₹54.16, so price/book is 16.43. That is not a bargain; it is a hope certificate. The business does show quality: ROCE 28.50%, debt/equity just 0.02, free cash flow ₹266 Cr, and promoter holding 74.69%, so owners have skin in the game. Latest quarter sales were ₹423 Cr and net profit ₹93 Cr. Over five years, revenue compounded 23.86%, which explains why the market awards P/E 87.69. But Buffett cares about consistency, and the recent numbers are not consistent: sales growth -27.10% and profit growth -31.23%. A Piotroski F-Score of 3/9 and FairStock Score 19/100 (RISKY) tell me financial momentum is weak. A 0.22% dividend yield offers almost no cash return while waiting. The 52-week range ₹579.15–₹977.00 shows the stock can swing violently. The moat may be scientific capability, but I cannot verify pricing power or durable competitive advantage from these figures alone. At 87.69 times earnings, any slowdown gets punished. I would want a wider margin of safety, positive growth reacceleration, and a higher Piotroski score before considering. Until then, this is a great business maybe, but not a great investment at this price. For an Indian retail investor, patience and price discipline matter more than biotech excitement.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer